CYP17A1/HDAC6-IN-1

CYP17A1/HDAC6-IN-1

• UNSPSC Description: CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity[1].
• Target Antigen: Cytochrome P450; HDAC
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cyp17a1-hdac6-in-1.html
• Solubility: 10 mM in DMSO
• Smiles: C[C@]12CCC3C(CC=C4C[C@@H](OC(CCCCCC(NO)=O)=O)CC[C@@]43C)C1CC=C2C5=CN=CC=C5
• Molecular Weight: 506.68
• References & Citations: [1]Ram Sharma, et al. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Lett. 2024 Feb 2:586:216666.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported